<DOC>
	<DOCNO>NCT02792868</DOCNO>
	<brief_summary>Study sample patient primary prevention , moderate cardiovascular risk ( n = 83 patient ) , normal , non-diabetic renal function . The investigator quantify phophocalcic intake excretion , realize food examination urine collection 24 particular . The investigator measure plasma level FGF23 serum calcium , phosphatemia , investigator calculate tubular reabsorption phosphate . The investigator conduct quantitative assessment coronary calcification non-injected CT scan , measure semi automate way Agatston calcium score . There analysis collinearity . An adjustment make confound variable generalize linear regression model .</brief_summary>
	<brief_title>Biological Phosphocalcic Metabolism Coronary Artery Calcifications</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Calcinosis</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>Hospitalization cardiovascular check Detection Centre Atherosclerosis Prevention ( CHU Rangueil Toulouse ) In primary prevention coronary heart disease Introducing intermediate cardiovascular risk accord European SCORE equation , say , risk cardiovascular death 10 year great equal 1 % le 5 % sign informed consent , Chronic renal failure patient estimate GFR le 60 mL / min / 1.73m2 , due alteration phosphate metabolism , Patients receive glucoselowering therapy , Patients fast blood glucose great capillary equal 1.10 g / l , confirm plasma glucose great equal 1.10g / l. The diuretic therapy patient ( due change urinary electrolyte ) HIVpositive patient HIV , antiretroviral ( due change urinary electrolyte ) Pregnant woman , Patients judicial protection , guardianship trusteeship .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>